• Associations between muscle measures, survival and toxicity in patients with limited disease small cell lung cancer receiving concurrent chemoradiotherapy 

      Halvorsen, Tarje Onsøien; Valan, Christine Damgaard; Jordhøy, Marit Slaaen; Grønberg, Bjørn Henning (Peer reviewed; Journal article, 2020)
      Background Standard treatment for patients with limited stage small cell lung cancer (LS SCLC) is concurrent platinum– etoposide chemotherapy and thoracic radiotherapy (TRT). Up to 30% of patients are cured, but severe ...
    • Associations between severe co-morbidity and muscle measures in advanced non-small cell lung cancer patients 

      Grønberg, Bjørn Henning; Valan, Christine Damgaard; Halvorsen, Tarje Onsøien; Sjøblom, Bjørg; Jordhøy, Marit Slaaen (Journal article; Peer reviewed, 2019)
      Introduction Several studies show that low skeletal muscle index (SMI) and low skeletal muscle density (SMD) are negative prognostic factors and associated with more toxicity from systemic therapy in cancer patients. ...
    • Associations between tumor mutations in cfDNA and survival in non-small cell lung cancer 

      Ottestad, Anine Larsen; Hong, Yan Dai; Halvorsen, Tarje Onsøien; Emdal, Elisabeth Fritzke; Wahl, Sissel Gyrid Freim; Grønberg, Bjørn Henning (Peer reviewed; Journal article, 2021)
      Introduction: Studies have indicated that detection of mutated KRAS or EGFR in circulating tumor DNA (ctDNA) from pre-treatment plasma samples is a negative prognostic factor for non-small cell lung cancer (NSCLC) pa-tients. ...
    • Changes in muscle measures during chemoradiotherapy in patients with limited stage small cell lung cancer 

      Valan, Christine Damgaard; Halvorsen, Tarje Onsøien; Jordhøy, Marit Slaaen; Grønberg, Bjørn Henning (Peer reviewed; Journal article, 2020)
      Background: Concurrent chemoradiotherapy is the recommended treatment for limited stage small cell lung cancer. Severe side‐effects, which might cause loss of muscle mass, are frequent. Low skeletal muscle index (SMI) and ...
    • Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer 

      Halvorsen, Tarje Onsøien; Sundstrøm, Stein Harald; Fløtten, Øystein; Brustugun, Odd Terje; Brunsvig, Paal Fr.; Aasebø, Ulf; Bremnes, Roy M.; Kaasa, Stein; Grønberg, Bjørn Henning (Journal article; Peer reviewed, 2016)
      Background: Many patients with limited disease small cell lung cancer (LD SCLC) suffer from comorbidity. Not all patients with comorbidity are offered standard treatment, though there is little evidence for such a policy. ...
    • Development of EirV3 - a computer-based tool for patient reported outcome measures in cancer 

      Krogstad, Hilde; Brunelli, Cinzia; Sand, Kari; Andersen, Eivind; Garresori, Herish; Halvorsen, Tarje Onsøien; Haukland, Ellinor Christin; Jordal, Frode; Kaasa, Stein; Loge, Jon Håvard; Løhre, Erik Torbjørn; Raj, Sunil Xavier; Hjermstad, Marianne Jensen (Journal article; Peer reviewed, 2017)
      Purpose Immediate transfer of patient-reported outcome measures (PROMs) for use in medical consultations is facilitated by electronic assessments. We aimed to describe the rationale and development of Eir version 3 (EirV3), ...
    • Prognostic and predictive factors in limited disease small-cell lung cancer 

      Valan, Christine Damgaard (Doctoral theses at NTNU;2020:203, Doctoral thesis, 2020)
      Lung cancer is the most common type of cancer and the leading cause of cancer related deaths. Small cell lung cancer (SCLC) is one of two main types of lung cancer. Concurrent chemoradiotherapy is recommended for SCLC if ...
    • The prognostic effect of KRAS mutations in non-small cell lung carcinoma revisited: A norwegian multicentre study 

      Wahl, Sissel Gyrid Freim; Hong, Yan Dai; Emdal, Elisabeth Fritzke; Berg, Thomas; Halvorsen, Tarje Onsøien; Ottestad, Anine Larsen; Lund-Iversen, Marius; Brustugun, Odd; Førde, Dagny; Paulsen, Erna-Elise; Donnem, Tom; Andersen, Sigve; Grønberg, Bjørn Henning; Richardsen, Elin (Peer reviewed; Journal article, 2021)
      Background: due to emerging therapeutics targeting KRAS G12C and previous reports with conflicting results regarding the prognostic impact of KRAS and KRAS G12C in non-small cell lung cancer (NSCLC), we aimed to investigate ...
    • Prognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapy 

      Wahl, Sissel Gyrid Freim; Hong, Yan Dai; Emdal, Elisabeth Fritzke; Ottestad, Anine Larsen; Dale, Vibeke Grotnes; Richardsen, Elin; Halvorsen, Tarje Onsøien; Grønberg, Bjørn Henning (Peer reviewed; Journal article, 2021)
      Droplet digital polymerase chain reaction (ddPCR) is a highly sensitive and accurate method for quantication of nucleic acid sequences. We used absolute quantication of mutated v-Ki-ras2 Kirsten rat sarcoma viral oncogene ...
    • Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer 

      Grønberg, Bjørn Henning; Halvorsen, Tarje Onsøien; Fløtten, Øystein; Brustugun, Odd Terje; Brunsvig, Paal Fr.; Aasebø, Ulf; Bremnes, Roy M.; Tollåli, Terje; Hornslien, Kjersti; Aksnessæther, Bjørg Y.; Liaaen, Erik Dyb; Sundstrøm, Stein Harald (Journal article; Peer reviewed, 2016)
      Background: Concurrent chemotherapy and thoracic radiotherapy (TRT) is recommended for limited disease small cell lung cancer (LD SCLC). Twice daily TRT is well documented, but not universally implemented – probably mainly ...
    • Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC 

      Halvorsen, Tarje Onsøien; Stokke, Kristin; Killingberg, Kristin Toftaker; Raj, Sunil Xavier; Sørhaug, Sveinung; Brustugun, Odd Terje; Fløtten, Øystein; Helbekkmo, Nina; Hornslien, Kjersti; Madebo, Tesfaye; Fluge, Sverre; Grønberg, Bjørn Henning (Peer reviewed; Journal article, 2020)
      Objectives: Two phase III trials show that maintenance pemetrexed therapy after platinum-doublet chemotherapy prolongs overall survival (OS) and progression free survival (PFS) in advanced non-squamous non-small-cell lung ...
    • Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement 

      Valan, Christine Damgaard; Slagsvold, Jens Erik; Halvorsen, Tarje Onsøien; Herje, Martin; Bremnes, Roy M.; Brunsvig, Paal Fr.; Brustugun, Odd Terje; Fløtten, Øystein; Levin, Nina; Sundstrøm, Stein Harald; Grønberg, Bjørn Henning (Journal article; Peer reviewed, 2018)
      Background/Aim: There are several definitions of limited disease (LD) in small cell lung cancer (SCLC), differing with respect to N3 disease accepted. We analyzed patients from a randomized trial comparing two schedules ...
    • Thoracic radiotherapy in limited disease small cell lung cancer 

      Halvorsen, Tarje Onsøien (Doctoral theses at NTNU;2017:7, Doctoral thesis, 2017)
      Norsk sammendrag: Lungekreft er den tredje hyppigste kreftformen, og den ledende årsaken til kreftrelaterte dødsfall. Småcellet lungekreft (SCLC) er den mest aggressive av to hovedtyper lungekreft, og forekommer nesten ...
    • Timing of severe toxicity from chemotherapy in patients with lung cancer 

      Sjøgren, Kristina; Jacobsen, Kristian Aalberg; Grønberg, Bjørn Henning; Halvorsen, Tarje Onsøien (Journal article; Peer reviewed, 2020)
      Background/Aim: The aim of this study was to investigate the timing of severe toxicity in lung cancer patients receiving chemotherapy. Patients and Methods: Patients with advanced non-small cell lung cancer or limited ...
    • Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer 

      Halvorsen, Tarje Onsøien; Herje, Martin; Levin, Nina; Bremnes, Roy M.; Brustugun, Odd Terje; Fløtten, Øystein; Kaasa, Stein; Sundstrøm, Stein Harald; Grønberg, Bjørn Henning (Journal article; Peer reviewed, 2016)
      Objectives Concurrent chemotherapy and thoracic radiotherapy (TRT) is recommended for limited disease small-cell lung cancer (LD SCLC). TRT should start as early as possible, often meaning with the second course due to ...